This site is intended for health professionals only

Published on 23 May 2012

Share this story:

Rivaroxaban supported by NICE


Oral rivaroxaban tablets have been recommended by the National 

Institute for Health and Clinical Excellence (NICE), the UK drug 

recommendation body, as a new treatment option for prevention of 

stroke and systemic embolism in patients with non-valvular atrial

fibrillation (AF) with one or more risk factors. 


The NICE recommendation gives eligible patients cared for by the 

UK health service with non-valvular AF in England and Wales 

access to rivaroxaban – the first one tablet per day, oral stroke

prevention medicine since the introduction of warfarin in the 1950s.


NICE estimates that almost half (46%) of AF patients who should be

receiving warfarin are not currently taking it. 



Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: